Anavex (AVXL) Life Sciences announced positive topline results from its placebo-controlled Phase 2 clinical study evaluating ANAVEX3-71 for the treatment of schizophrenia in adults on stable antipsychotic medication. The study successfully achieved its primary endpoint, demonstrating that ANAVEX3-71 was safe and well-tolerated. The safety profile was consistent with previous studies of ANAVEX3-71 in healthy volunteers, with no serious treatment-emergent adverse events and no severe TEAEs reported in either Part A or Part B of the study.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVXL:
- Anavex announces publication on oral blarcamesine Phase IIb/III trial
- Promising Clinical Data and Market Potential Drive Buy Rating for Anavex Life Sciences
- Anavex announces latest findings for blarcamesine
- Anavex Life Sciences Earnings Call: Promising Alzheimer’s Progress Amid Operational Challenges
- Largest borrow rate increases among liquid names